Rinku Sutradhar1,2,3, Armend Lokku1, Lisa Barbera2,3,4. 1. Department of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 2. Institute for Clinical Evaluative Sciences, Toronto, Toronto, Ontario, Canada. 3. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. 4. Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Little is known about opioid prescribing among individuals who have survived cancer. Our aim is to examine a predominantly socio-economically disadvantaged population for differences in opioid prescribing rates among cancer survivors compared with matched controls without a prior diagnosis of cancer. METHODS: This was a retrospective population-wide matched cohort study. Starting in 2010, individuals residing in Ontario, Canada, who were 18 to 64 years of age and at least 5 years past their cancer diagnosis were matched to controls without a prior cancer diagnosis based on sex and calendar year of birth. Follow-up was terminated at any indication of cancer recurrence, second malignancy, or new cancer diagnosis. To examine the association between survivorship and the rate of opioid prescriptions, an Andersen-Gill recurrent event regression model was implemented, adjusting for numerous individual-level characteristics and also accounting for the matched design. RESULTS: The rate of opioid prescribing was 1.22 times higher among survivors than among their corresponding matched controls (adjusted relative rate, 1.22; 95% CI, 1.11-1.34). Individuals from lower income quintiles who were younger, were from rural neighborhoods, and had more comorbidities had significantly higher prescribing rates. Sex was not associated with prescribing rates. This increased rate of opioid prescribing was also seen among survivors who were 10 or more years past their cancer diagnosis (compared with their controls). CONCLUSION: This study demonstrates substantially higher opioid prescribing rates among cancer survivors, even long after attaining survivorship. This raises concerns about the diagnosis and management of chronic pain problems among survivors stemming from their cancer diagnosis or treatment. Cancer 2017;123:4286-4293.
BACKGROUND: Little is known about opioid prescribing among individuals who have survived cancer. Our aim is to examine a predominantly socio-economically disadvantaged population for differences in opioid prescribing rates among cancer survivors compared with matched controls without a prior diagnosis of cancer. METHODS: This was a retrospective population-wide matched cohort study. Starting in 2010, individuals residing in Ontario, Canada, who were 18 to 64 years of age and at least 5 years past their cancer diagnosis were matched to controls without a prior cancer diagnosis based on sex and calendar year of birth. Follow-up was terminated at any indication of cancer recurrence, second malignancy, or new cancer diagnosis. To examine the association between survivorship and the rate of opioid prescriptions, an Andersen-Gill recurrent event regression model was implemented, adjusting for numerous individual-level characteristics and also accounting for the matched design. RESULTS: The rate of opioid prescribing was 1.22 times higher among survivors than among their corresponding matched controls (adjusted relative rate, 1.22; 95% CI, 1.11-1.34). Individuals from lower income quintiles who were younger, were from rural neighborhoods, and had more comorbidities had significantly higher prescribing rates. Sex was not associated with prescribing rates. This increased rate of opioid prescribing was also seen among survivors who were 10 or more years past their cancer diagnosis (compared with their controls). CONCLUSION: This study demonstrates substantially higher opioid prescribing rates among cancer survivors, even long after attaining survivorship. This raises concerns about the diagnosis and management of chronic pain problems among survivors stemming from their cancer diagnosis or treatment. Cancer 2017;123:4286-4293.
Authors: Jessica D McDermott; Megan Eguchi; William A Stokes; Arya Amini; Mohammad Hararah; Ding Ding; Allison Valentine; Cathy J Bradley; Sana D Karam Journal: Otolaryngol Head Neck Surg Date: 2018-11-06 Impact factor: 3.497
Authors: Jacob C Cogan; Rohit R Raghunathan; Melissa P Beauchemin; Melissa K Accordino; Elena B Elkin; Alexander Melamed; Jason D Wright; Dawn L Hershman Journal: Breast Cancer Res Treat Date: 2021-06-04 Impact factor: 4.872
Authors: Julie Hallet; Laura E Davis; Elie Isenberg-Grzeda; Alyson L Mahar; Haoyu Zhao; Victoria Zuk; Lesley Moody; Natalie G Coburn Journal: Oncologist Date: 2020-02-26
Authors: Amy J Davidoff; Maureen E Canavan; Shelli Feder; Shiyi Wang; Ella Sheinfeld; Erin E Kent; Jennifer Kapo; Carolyn J Presley Journal: Support Care Cancer Date: 2019-10-21 Impact factor: 3.603
Authors: Carolyn W Swenson; Neil S Kamdar; Kristian Seiler; Daniel M Morgan; Paul Lin; Sawsan As-Sanie Journal: Am J Obstet Gynecol Date: 2018-06-19 Impact factor: 8.661